The characteristics and clinical course of patients with COVID-19 who received invasive mechanical ventilation in Osaka, Japan

Int J Infect Dis. 2021 Jan:102:282-284. doi: 10.1016/j.ijid.2020.10.051. Epub 2020 Oct 27.

Abstract

Objective: To describe the detailed clinical course of patients with coronavirus disease 2019 (COVID-19) who received invasive mechanical ventilation.

Methods: We conducted a case series of patients with COVID-19 who received invasive mechanical ventilation in Osaka, Japan, between January 29 and May 28, 2020. We describe the patient characteristics and clinical course from onset. Additionally, we fitted logistic regression models to investigate the associations between patient characteristics and the 30-day mortality rate.

Results: A total of 125 patients who received invasive mechanical ventilation (median age [interquartile range], 68 [57-73] years; male, 77.6%) were enrolled. Overall, the 30-day mortality was 24.0%, and the median (interquartile range) length of ICU stay and length of invasive mechanical ventilation use were 16 (12-29) days and 13 (9-26) days, respectively. From clinical onset, 121 patients (96.8%) were intubated within 14 days. In multivariable logistic regression analysis, age of 65 years or older (odds ratio, 3.56; 95% confidence interval, 1.21-10.49; P = 0.02) and male sex (odds ratio, 3.75; 95% confidence interval, 1.00-11.24, P = 0.04) were significantly associated with a higher 30-day mortality rate.

Conclusions: In this case series of patients with COVID-19 who received invasive mechanical ventilation in Japan, the 30-day mortality rate was 24.0%, and age 65 years or older and male sex were associated with higher 30-day mortality rate.

Keywords: 30-day mortality rate; COVID-19; Epidemiology; Invasive mechanical ventilation.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 / mortality
  • COVID-19 / therapy*
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Respiration, Artificial / methods*
  • Retrospective Studies
  • SARS-CoV-2*